Decreased metabolism in the cerebral cortex in early-stage huntington's disease: A possible biomarker of disease progression?

Journal of Clinical Neurology (Korea)

Volumn 9, Issue 1, 2013, Pages 21-25

  Shin, Hyeeun ^a   Kim, Man Ho ^b   Lee, Su Jin ^c   Lee, Kyung Han ^d   Kim, Mi Jung ^e   Kim, Ji Sun ^f   Cho, Jin Whan ^f  

^a Eulji General Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f NONE

Author keywords

Biomarker; Cortical metabolism; FDG PET; Huntington's disease; Progression

Indexed keywords

EID: 84887845775     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2013.9.1.21     Document Type: Article

References (21)

1. ACMG/ASHG statement. Laboratory guidelines for Huntington disease genetic testing. The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. Am J Hum Genet 1998;62:1243-1247.
2. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401-1406.
3. Hersch S, Rosas H, Ferrante R. Neuropathology and pathophysiology of Huntington's disease. New York: McGraw-Hill, 2004.
4. Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurolo-gy 1987;37:1441-1447.
5. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987;316:357-362.
6. Grafton ST, Mazziotta JC, Pahl JJ, St George-Hyslop P, Haines JL, Gusella J, et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol 1990;28:614-621.
7. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119:2085-2095.
8. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain 2008;131:1057-1068.
9. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante R., Salat DH, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002;58:695-701.
10. Martin WR, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington's disease. Neurology 1992; 42:223-229.
11. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990;113:1405-1423.
12. Ashizawa T, Wong LJ, Richards CS, Caskey CT, Jankovic J. CAG repeat size and clinical presentation in Huntington's disease. Neurology 1994;44:1137-1143.
13. Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, et al. Trinucleotide repeat length and progression of illness in Hun-tington's disease. J Med Genet 1994;31:872-874.
14. Esmaeilzadeh M, Ciarmiello A, Squitieri F. Seeking brain biomarkers for preventive therapy in Huntington disease. CNS Neurosci Ther 2011; 17:368-386.
15. Squitieri F, Cannella M, Frati L. Molecular medicine: Predicting and preventing Huntington's disease. Neurol Sci 2008;29:205-207.
16. Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Hun-tington disease. Arch Neurol 1996;53:1293-1296.
17. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Hunting-ton's disease in asymptomatic atrisk persons. Neurology 1994;44: 823-828.
18. Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length. Ann Neurol 1998;43:253-255.
19. Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, et al. The distribution of structural neuropathology in preclinical Huntington's disease. Brain 2002;125:1815-1828.
20. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology 2003;60:1615-1620.
21. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsz-tein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006;47:215-222.